{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:27:59Z","timestamp":1753892879275,"version":"3.41.2"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T00:00:00Z","timestamp":1652140800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) delta variant has been hypothesized to decrease the efficacy of COVID-19 vaccines. Factors associated with infections with SARS-CoV-2 after vaccination are unknown. In this observational cohort study, we examined two groups in Harris County, Texas: (1) individuals with positive Nucleic Acid Amplification test between 12\/14\/2020 and 9\/30\/2021 and (2) the subset of individuals fully vaccinated in the same time period. Infected individuals were classified as a breakthrough if their infection occurred 14 days after their vaccination had been completed. Among fully vaccinated individuals, demographic and vaccine factors associated with breakthrough infections were assessed. Of 146,731 positive SARS-CoV-2 tests, 7.5% were breakthrough infections. Correlates of breakthrough infection included young adult age, female, White race, and receiving the Janssen vaccine, after adjustments including the amount of community spread at the time of infection. Vaccines remained effective in decreasing the probability of testing positive for SARS-CoV-2. The data indicate that increased vaccine booster uptake would help decrease new infections.<\/jats:p>","DOI":"10.3389\/fpubh.2022.856532","type":"journal-article","created":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T09:47:53Z","timestamp":1652176073000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Trends and Correlates of Breakthrough Infections With SARS-CoV-2"],"prefix":"10.3389","volume":"10","author":[{"given":"Jose-Miguel","family":"Yamal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Savitri","family":"Appana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis","family":"Leon-Novelo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Bakota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanqing","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreela","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alanna C.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dritana","family":"Marko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen H.","family":"Linder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Rector","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn K.","family":"Jetelina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Boerwinkle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcia","family":"de Oliveira Otto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26. COV2 S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","article-title":"Covid-19 Breakthrough infections in vaccinated health care workers","volume":"385","author":"Bergwerk","year":"2021","journal-title":"N Engl J Med."},{"volume-title":"Epidemiology for Public Health Practice, Vol. 3.","year":"2003","author":"Friis","key":"B5"},{"key":"B6","unstructured":""},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1101\/2021.07.19.21260808","article-title":"Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas","author":"Musser","year":"2021"},{"key":"B8","unstructured":"American Community Survey 5-Year Estimates2019"},{"key":"B9","doi-asserted-by":"publisher","first-page":"taab124","DOI":"10.1093\/jtm\/taab124","article-title":"The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus","volume":"28","author":"Liu","year":"2021","journal-title":"J Travel Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B16172 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"eabl9551","DOI":"10.1101\/2021.09.02.21262979","article-title":"REACT-1 round 13 final report: exponential growth, high prevalence of SARS-CoV-2 and vaccine effectiveness associated with Delta variant in England during May to July 2021","volume":"374","author":"Elliott","year":"2021","journal-title":"Science."},{"key":"B12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.15585\/mmwr.mm7021e3","article-title":"COVID-19 Vaccine breakthrough infections reported to CDC \u2014 United States, January 1\u2013April 30, 2021","volume":"70","year":"2021","journal-title":"Morb Mortal Weekly Rep"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.856532\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,10]],"date-time":"2022-05-10T09:47:55Z","timestamp":1652176075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2022.856532\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,10]]},"references-count":12,"alternative-id":["10.3389\/fpubh.2022.856532"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2022.856532","relation":{},"ISSN":["2296-2565"],"issn-type":[{"type":"electronic","value":"2296-2565"}],"subject":[],"published":{"date-parts":[[2022,5,10]]},"article-number":"856532"}}